Patents by Inventor Frédéric Deschaseaux

Frédéric Deschaseaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC PEPTIDES
    Publication number: 20240075097
    Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.
    Type: Application
    Filed: December 27, 2022
    Publication date: March 7, 2024
    Applicants: UNIVERSITE TOULOUSE III-PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANÇAIS DU SANG
    Inventors: Jean-Philippe COMBIER, Anne PREL, Frédéric DESCHASEAUX
  • Therapeutic peptides
    Patent number: 11607443
    Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 21, 2023
    Assignees: UNIVERSITE TOULOUSE III-PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANçAIS DU SANG
    Inventors: Jean-Philippe Combier, Anne Prel, Frédéric Deschaseaux
  • SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20220023325
    Abstract: The present invention relates to a TLR4 (toll-like receptor 4) specific antagonist for use in the treatment of multiple myeloma in a subject suffering from multiple myeloma, and also to an antitumor pharmaceutical combination comprising (i) a TLR4-specific antagonist and (ii) a chemotherapy agent for simultaneous, separate or sequential use in the treatment of multiple myeloma.
    Type: Application
    Filed: December 22, 2017
    Publication date: January 27, 2022
    Inventors: Nicolas ESPAGNOLLE, Frédéric DESCHASEAUX, Luc SENSEBE, Philippe BOURIN
  • THERAPEUTIC PEPTIDES
    Publication number: 20200000878
    Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.
    Type: Application
    Filed: December 22, 2017
    Publication date: January 2, 2020
    Applicants: UNIVERSITE TOULOUSE III-PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANÇAIS DU SANG
    Inventors: Jean-Philippe COMBIER, Anne PREL, Frédéric DESCHASEAUX
  • METHOD FOR OBTAINING HUMAN BROWN/BEIGE ADIPOCYTES
    Publication number: 20180216070
    Abstract: The present invention concerns a method of producing brown/beige adipocytes from white adipose tissue cells and/or mesenchymal stem cells, in particular from subcutaneous white adipose tissue cells, and the use of said brown/beige adipocytes in a cell based therapy of a subject or in screening platforms.
    Type: Application
    Filed: July 8, 2016
    Publication date: August 2, 2018
    Inventors: FREDERIC DESCHASEAUX, FABIEN GUILLOTON, SANDRA MULLER, LUC SENSEBE, LOUIS CASTEILLA, AUDREY CARRIERE-PAZAT
  • HLA-G isoform for use in the treatment of a disease associated with bone resorption
    Patent number: 9375464
    Abstract: Novel use of HLA-G isoforms in the treatment or prevention of diseases in which bone resorption is observed.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: June 28, 2016
    Assignees: Etablissement Francais du Sang, Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Frédéric Deschaseaux, Luc Sensebe, Nathalie Rouas-Freiss
  • HLA-G Isoform for use in the Treatment of a Disease Associated with Bone Resorption
    Publication number: 20140065184
    Abstract: Novel use of HLA-G isoforms in the treatment or prevention of diseases in which bone resorption is observed.
    Type: Application
    Filed: November 23, 2011
    Publication date: March 6, 2014
    Applicant: ETABLISSEMENT FRANCAIS DU SANG
    Inventors: Frédéric Deschaseaux, Luc Sensebe, Nathalie Rouas-Freiss
  • USE OF AN ISOFORM OF HLA-G AS AN OSTEOGENESIS MARKER
    Publication number: 20130109020
    Abstract: The invention relates to the use of at least one isoform of HLA-G as a marker for assessing osteogenesis in mammals.
    Type: Application
    Filed: November 23, 2010
    Publication date: May 2, 2013
    Applicants: Etablissement Francais Du Sang, Commissariat A L'Energie Atomique Et Aux Energies Alternatives
    Inventors: Frederic Deschaseaux, Luc Sensebe, Nathalie Rouas-Freiss, Abderrahim Naji, Edgardo Delfino